Review of significant microvascular surgical breakthroughs involving the heart and lungs in rats

Chung, Wook-Sung; Cho, Charles; Kim, Sung Hoon; Lee, Sun; Tarin, Tatum; Chung, Rex; Housman, Leland B.; Jamieson, Stuart W.

doi:10.1002/(sici)1098-2752(1999)19:2<71::aid-micr6>3.0.co;2-5

Cited by 5 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To experimentally study the pathogenesis and possible interventions of OAD, the development of a simple animal model that accurately reflects the histological features found in human lung transplant recipients has been a highly desirable goal. Experience with rat whole lung transplant models showed that these models were time‐consuming, technically demanding and animals showed a considerably high variability within the study groups [12–14]. Furthermore, obliterative lesions require a substantial time to develop, histologic evaluation of rat small airway is difficult and lesions are not always evident in this model [15].…”

Section: Discussionmentioning

confidence: 99%

Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease

et al. 2006

View full text Add to dashboard Cite

Summary This study examined the efficacies of sirolimus and the novel immunosuppressive agent FK778 to prevent obliterative airway disease (OAD). Tracheae from Brown–Norway donors were heterotopically transplanted in the greater omentum of Lewis rats. Recipients were treated for 28 days with sirolimus (0.5 or 2 mg/kg), FK778 (5 or 20 mg/kg), or combination regimens (0.5 + 5 mg/kg, 2 + 20 mg/kg). Tracheal segments were evaluated for degree of luminal obliteration, percentage of luminal epithelial cell coverage, and peritracheal infiltration. In vitro smooth muscle cell (SMC) proliferation and migration assays were performed to assess direct nonimmune‐related effects of the drugs. Sirolimus 2 mg/kg and FK778 20 mg/kg effectively reduced graft infiltration and prevented airway obliteration, whereas FK778 5 mg/kg was insufficient. Sirolimus 0.5 mg/kg at least showed moderate inhibitory effects on luminal obliteration and graft infiltration. Combination regimens revealed no significant beneficial effects. Both sirolimus and FK778 barely showed preserved epithelial coverage. Within the range of relevant concentrations, FK778 showed more potent anti‐proliferative and anti‐migratory effects on SMC in vitro than sirolimus. Both agents proved effective to prevent OAD development without preserving relevant amounts of epithelium. The anti‐proliferative potency on SMCs seems to be an especially important mechanism for FK778. De novo combination regimens revealed no beneficial interaction and thus remain doubtful.

show abstract

Section: Discussionmentioning

confidence: 99%

Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Techniques have included developing surgical methods for organ transplants, vessel transplants and prostheses, arteriovenous shunts, blood pressure studies, electromagnetic flow probes, and microangiography (Bishop, 1980;Chung et al, 1999;Zhong, 1999). Techniques have included developing surgical methods for organ transplants, vessel transplants and prostheses, arteriovenous shunts, blood pressure studies, electromagnetic flow probes, and microangiography (Bishop, 1980;Chung et al, 1999;Zhong, 1999).…”

Section: Cardiovascular Techniquesmentioning

confidence: 99%